Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria
Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.
You may also be interested in...
Pfizer has continued its recent deal-making spree with the acquisition of a "controlling interest" in Redvax, a spin-off from Redbiotec, a privately held Swiss biopharmaceutical company.
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.